公开(公告)号：US12115150B2

公开(公告)日：2024-10-15

申请号：US17900235

申请日：2022-08-31

Applicant: RedHill Biopharma Ltd.

Inventor： Dror Ben-Asher ,  Reza Fathi ,  Mark Levitt ,  Ofra Barnett

IPC: A61K31/4409 ,  A61K9/48 ,  A61P31/14

CPC classification number: A61K31/4409 ,  A61K9/48 ,  A61P31/14

Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.

公开(公告)号：US12109301B2

公开(公告)日：2024-10-08

申请号：US18055595

申请日：2022-11-15

Applicant: Massachusetts Institute of Technology ,  The General Hospital Corporation

Inventor： Xiang Li ,  Michael J. Cima ,  Brian H. Eisner

IPC: A61K9/00 ,  A61K31/4409 ,  A61K31/4422 ,  A61K45/06

CPC classification number: A61K9/0034 ,  A61K9/0002 ,  A61K31/4409 ,  A61K31/4422 ,  A61K45/06

Abstract: Provided are formulations and methods for treating one or more genitourinary conditions. The formulations may include a therapeutic agent that includes a calcium channel blocker, a rho kinase inhibitor, or a combination thereof. The methods may include locally administering a therapeutic agent into a ureter. Systems for delivering a therapeutic agent also are provided.

公开(公告)号：US20240325389A1

公开(公告)日：2024-10-03

申请号：US17907324

申请日：2021-03-26

Applicant: UNIVERSITÉ PARIS CITÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Inventor： Jean-Philippe HERBEUVAL ,  Benoit SCHNEIDER ,  Nassima BEKKADOUR ,  Vincent BAUDOUIN

IPC: A61K31/506 ,  A61K31/404 ,  A61K31/4409 ,  A61K31/4439 ,  A61K45/06 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/18 ,  A61P37/06

CPC classification number: A61K31/506 ,  A61K31/404 ,  A61K31/4409 ,  A61K31/4439 ,  A61K45/06 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/18 ,  A61P37/06

Abstract: The present invention relates to an inhibitor of the ROCK-PDK1 protein kinase complex for use thereof as an anti-inflammatory and anti-interferon agent. The present invention also relates to a pharmaceutical composition comprising an inhibitor of the ROCK-PDK1 protein kinase complex as active principle and at least one pharmaceutically acceptable excipient and/or carrier and/or a diluent and/or a pharmaceutically acceptable vehicle. The present invention also relates to the use of said one pharmaceutical composition in the prevention and/or the treatment of inflammatory diseases, viral and/or bacterial infections and autoimmune diseases.

公开(公告)号：US12054493B2

公开(公告)日：2024-08-06

申请号：US17143326

申请日：2021-01-07

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D493/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/00 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C317/44 ,  C07C323/42 ,  C07C323/62 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04

CPC classification number: C07D493/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/001 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C317/44 ,  C07C323/42 ,  C07C323/62 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04 ,  C07B2200/05 ,  C07B2200/07 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/44 ,  C07C2602/46 ,  C07C2603/74

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240254075A1

公开(公告)日：2024-08-01

申请号：US18558726

申请日：2022-05-06

Applicant: Autobahn Therapeutics, Inc.

Inventor： Brian Andrew STEARNS ,  Jill Melissa BACCEI ,  Jason Randall HARRIS

IPC: C07C235/20 ,  A61K31/16 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/455 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61P25/00 ,  C07C235/16 ,  C07C235/22 ,  C07C235/24 ,  C07C243/28 ,  C07C255/29 ,  C07C259/06 ,  C07C313/02 ,  C07C317/28 ,  C07D205/04 ,  C07D213/75 ,  C07D237/20 ,  C07D237/22 ,  C07D239/42 ,  C07D241/20 ,  C07D261/14 ,  C07D295/18 ,  C07D305/08

CPC classification number: C07C235/20 ,  A61K31/16 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/42 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/455 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505 ,  A61K31/5375 ,  A61P25/00 ,  C07C235/16 ,  C07C235/22 ,  C07C235/24 ,  C07C243/28 ,  C07C255/29 ,  C07C259/06 ,  C07C313/02 ,  C07C317/28 ,  C07D205/04 ,  C07D213/75 ,  C07D237/20 ,  C07D237/22 ,  C07D239/42 ,  C07D241/20 ,  C07D261/14 ,  C07D295/18 ,  C07D305/08 ,  C07C2601/02 ,  C07C2601/14

Abstract: Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restricted FAAH inhibitor.

公开(公告)号：US12016873B2

公开(公告)日：2024-06-25

申请号：US17883491

申请日：2022-08-08

Applicant: INSMED INCORPORATED

Inventor： Gina Eagle ,  Renu Gupta

IPC: A61K31/7036 ,  A61K9/00 ,  A61K9/127 ,  A61K31/04 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P31/04

CPC classification number: A61K31/7036 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0078 ,  A61K9/127 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P31/04

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：US20240197666A1

公开(公告)日：2024-06-20

申请号：US18283787

申请日：2022-03-23

Applicant: K-Gen Therapeutics, Inc.

Inventor： Chun Jiang ,  Ruihong CHEN

IPC: A61K31/22 ,  A61K31/122 ,  A61K31/222 ,  A61K31/223 ,  A61K31/23 ,  A61K31/232 ,  A61K31/336 ,  A61K31/397 ,  A61K31/405 ,  A61K31/415 ,  A61K31/421 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4409 ,  A61K39/395 ,  A61K45/06 ,  A61P17/02 ,  A61P35/00 ,  A61K39/00

CPC classification number: A61K31/22 ,  A61K31/122 ,  A61K31/222 ,  A61K31/223 ,  A61K31/23 ,  A61K31/232 ,  A61K31/336 ,  A61K31/397 ,  A61K31/405 ,  A61K31/415 ,  A61K31/421 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4409 ,  A61K39/3955 ,  A61K45/06 ,  A61P17/02 ,  A61P35/00 ,  A61K2039/505

Abstract: This present disclosure relates to a method of stimulating an immune response using compounds that activate protein kinase C (PKC), including for treatment of a cancer, a precancerous lesion, a benign tumor, or a wound.

公开(公告)号：US20240156846A1

公开(公告)日：2024-05-16

申请号：US18113981

申请日：2023-02-24

Applicant: Arizona Board of Regents on Behalf of the University of Arizona ,  THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： Rui Chang ,  Patrick T. Ronaldson ,  Qianying He ,  Wassim ELYAMAN ,  Elizabeth BRADSHAW ,  Kuixi ZHU

IPC: A61K31/7028 ,  A61K31/26 ,  A61K31/357 ,  A61K31/404 ,  A61K31/4409 ,  A61K31/5375 ,  A61K45/06 ,  A61P25/28

CPC classification number: A61K31/7028 ,  A61K31/26 ,  A61K31/357 ,  A61K31/404 ,  A61K31/4409 ,  A61K31/5375 ,  A61K45/06 ,  A61P25/28

Abstract: This invention relates generally to neurodegenerative diseases and conditions (e.g., Alzheimer's disease) characterized with dysfunctional energetic function, unregulated microglia phagocytic activity and other related de-regulated biological functions. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions capable of protecting neurons from cell death and unregulated microglia phagocytic activity.

公开(公告)号：US20240130984A1

公开(公告)日：2024-04-25

申请号：US18492627

申请日：2023-10-23

Applicant: CALGENT BIOTECHNOLOGY CO., LTD.

Inventor： Yun YEN ,  Jing-Ping LIOU ,  Chien Huang LIN

IPC: A61K31/166 ,  A61K9/20 ,  A61K9/48 ,  A61K31/40 ,  A61K31/404 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/519 ,  A61K31/5375 ,  A61K45/06 ,  A61P11/00 ,  C07C15/00

CPC classification number: A61K31/166 ,  A61K9/20 ,  A61K9/48 ,  A61K31/40 ,  A61K31/404 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4453 ,  A61K31/47 ,  A61K31/4706 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/505 ,  A61K31/519 ,  A61K31/5375 ,  A61K45/06 ,  A61P11/00 ,  C07C15/00 ,  A61K9/0019

Abstract: The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

公开(公告)号：US11918560B2

公开(公告)日：2024-03-05

申请号：US17344430

申请日：2021-06-10

Applicant: RedHill Biopharma Ltd.

Inventor： Dror Ben-Asher ,  Reza Fathi

IPC: A61K31/435 ,  A61K9/00 ,  A61K9/48 ,  A61K31/4409 ,  A61M31/00 ,  A61P31/14

CPC classification number: A61K31/435 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/4409 ,  A61M31/00 ,  A61P31/14

Abstract: The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.